April 12, 2021

Dannielle Engle awarded prestigious pancreatic cancer research grant honoring Ruth Bader Ginsburg

Salk Nachrichten


Dannielle Engle awarded prestigious pancreatic cancer research grant honoring Ruth Bader Ginsburg

LA JOLLA—Salk Assistant Professor Dannielle Engle was selected as the first recipient of the Lustgarten Foundation-AACR Career Development Award for Pancreatic Cancer Research in Honor of Ruth Bader Ginsburg, the late Supreme Court Justice and women’s rights pioneer.

Engle will receive $300,000 to fund her pancreatic cancer research, which is focused on understanding how we can intercept the signals causing pancreatic cancer to metastasize and become so deadly. The award, along with a similar grant honoring Rep. John Lewis, was announced Sunday, April 11, during AACR’s annual meeting.

“We are thrilled Dannie’s cancer research is continuing to receive notable recognition and support,” says Salk President Rusty Gage. “The dedication of early-career researchers like Dannie is changing the future of pancreatic cancer diagnosis and treatment.”

Each year, more than 45,000 Americans lose their lives to pancreatic cancer—now the third-leading cause of cancer-related deaths with a five-year relative survival rate of 10 percent. Through these awards, the Lustgarten Foundation and the AACR seek to help close the gap in the number of early-career women and under-represented scientists applying for and receiving funding to conduct research leading to a better understanding and treatment of pancreatic cancer.

“I truly appreciate the Lustgarten Foundation for recognizing my work in this generous way,” says Engle, a member of Salk’s National Cancer Institute (NCI)-designated Salk Cancer Center. “This support will accelerate my lab’s work in finding better treatment options for people diagnosed with pancreatic cancer.”

Forschungsbereiche

Für weitere Informationen

Büro für Kommunikation
Telefon: (858) 453-4100
press@salk.edu

Das Salk-Institut für biologische Studien:

Das Salk Institute ist ein unabhängiges, gemeinnütziges Forschungsinstitut, das 1960 von Jonas Salk, dem Entwickler des ersten sicheren und wirksamen Polio-Impfstoffs, gegründet wurde. Die Aufgabe des Instituts besteht darin, grundlegende, kooperative und risikofreudige Forschung voranzutreiben, die sich mit den dringendsten Herausforderungen der Gesellschaft befasst, darunter Krebs, Alzheimer und die Gefährdung der Landwirtschaft. Diese Grundlagenforschung bildet die Basis für alle translationalen Bemühungen und führt zu Erkenntnissen, die neue Medikamente und Innovationen weltweit ermöglichen.